Egan-Jones Recommends Poniard Shareholders Vote "FOR" Poniard's Proposed Merger With ALLOZYNE and Reverse Stock Split

Poniard Pharmaceuticals, Inc. PARD announced today that Egan-Jones Proxy Services, an independent proxy advisory firm, has recommended that Poniard shareholders vote "FOR" all proposals listed in the Company's proxy statement materials, including the proposal related to the issuance of stock in connection with its proposed merger with ALLOZYNE, Inc. and the proposal to effect a reverse stock split of Poniard's outstanding common stock at a ratio of 1-for-40.